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Objective: Interleukin-10 is a pleiotrophic cytokine with variable effects on the
alloimmune response, depending on the experimental model system. The purpose of
this study was to determine the role of regulated interleukin-10 expression on the
development of chronic rejection in heart transplantation, or cardiac allograft
vasculopathy.
Methods: Donor hearts from B6.C-H2bm12 mice were transplanted into wild-type
and interleukin-10 transgenic recipients. In interleukin-10 transgenic recipients,
murine interleukin-10 cytokine is produced under the control of human interleukin-2
promoter. Donor hearts were sacrificed at days 7 and 24. No immunosuppression
was used. Intimal proliferation was measured morphometrically. Intragraft cellular
infiltrate was defined by both immunohistochemistry and flow cytometry. Intracel-
lular cytokine staining assay was performed to determine both the type and source
of intragraft cytokines.
Results: Hearts transplanted into wild-type recipients developed severe cardiac
allograft vasculopathy by 24 days. Intimal lesions were absent in the donor hearts
transplanted into interleukin-10 transgenic recipients. The number of graft-infiltrat-
ing T lymphocytes and the percentage of interleukin-2/interferon- producing T
lymphocytes were markedly reduced in interleukin-10 transgenic recipients. Finally,
the overexpression of interleukin-10 resulted in the decline of graft-infiltrating
macrophages at all time points.
Conclusions: Regulated expression of interleukin-10 inhibits cardiac allograft vas-
culopathy development via reduction of mononuclear cell recruitment and alteration
of their cytokine profile. This strategy may prove beneficial in controlling the
alloimmune response in solid organ transplants.
Cardiac allograft vasculopathy (CAV), the primary manifestation ofchronic rejection in transplanted hearts, is the leading cause of latedeath in heart transplant recipients. The pathogenesis of CAVremains incompletely understood. Our laboratory has characterizeda major histocompatibility complex (MHC) class II mismatchedmodel of CAV (B6C.H-2bm12 donors and C57BL/6 recipients)
where the development of intimal lesions is absolutely contingent on the presence
of CD4 lymphocytes.1 In addition to playing a role in the activation of antigen
presenting cells (APCs) via CD40 signaling,2 we found that graft-infiltrating CD4
lymphocytes were the primary source of the proinflammatory cytokines (Th-1),
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interleukin (IL)-2 and interferon (IFN)-.1 Importantly, nei-
ther CD4, nor CD8 lymphocytes secreted the anti-in-
flammatory cytokines (Th-2), IL-10, or IL-4.1
In organ transplantation, Th-1 cytokines are thought to
promote allograft rejection by activating effector cells such
as cytotoxic T lymphocytes or macrophages. In contrast,
Th-2 cytokines are thought to inhibit the alloimmune re-
sponse, primarily by decreasing antigen presentation and
antigen-specific T lymphocyte activation.3,4 Not surpris-
ingly, several investigators have sought to prevent allograft
rejection by overexpressing Th-2 cytokines, including IL-
10. Overall, the reported outcomes have been contradictory.
Qin and colleagues5 reported that retroviral-mediated trans-
fer of viral IL-10 gene prolonged murine cardiac allograft
survival in an acute rejection model. In contrast, Qian and
colleagues6 illustrated that systemic administration of IL-10
paradoxically led to accelerated acute rejection. Finally,
Furukawa and colleagues7 examined the effects of IL-10
treatment on chronic rejection and observed that exogenous
IL-10 exacerbated CAV development. The contradictory
nature of the cited findings is in part related to the pleiotro-
phic properties of IL-10, and in part to the dose, timing, and
duration of IL-10 therapy.
Because CAV development in our model is dependent on
IFN- secretion,8,9 we hypothesized that the selective ex-
pression of IL-10 by graft-infiltrating T lymphocytes would
inhibit the secretion of IFN- within the donor heart, and
subsequently abrogate CAV development. To address this
hypothesis, we used an IL-10 transgenic mouse recipient, in
which mouse IL-10 is driven by the T-lymphocyte–specific
human IL-2 promoter.10 Activation of IL-2 promoter in
recipient T-lymphocytes (ie, in an allogeneic response) re-
sults in overexpression of IL-10, at sites of T-lymphocyte
activation such as primary and secondary lymph nodes and
in the allograft. This study sought to determine the effect of
regulated IL-10 production on intimal thickening, mononu-
clear cell infiltration, and the cytokine phenotype of graft-
infiltrating lymphocytes. Our findings suggest that regulated
IL-10 expression markedly reduces the number of graft-
infiltrating T lymphocytes and macrophages, alters their
cytokine profile, and inhibits the development of CAV.
Materials and Methods
Animals
Adult female B6C.H-2bm12 and wild-type C57Bl/6 mice (7-10
weeks old) were purchased from Jackson Laboratories (Bar Har-
bor, Me). C57Bl/6 mice bearing the IL-10 transgene under the
control of the human IL-2 promoter were generated as previously
described.10 The B6C.H-2bm12 and C57Bl/6 strains differ at the
I-A locus of MHC II but are identical at MHC I and minor MHC
loci. The mice were housed under conventional conditions and fed
water and standard rodent laboratory chow (Purina Mills, Inc., St
Louis, Mo) ad libitum. All animals received humane care in
compliance with UCLA guidelines and the Principles of Labora-
tory Animal Care, published by the National Institute of Health
(NIH Publication No. 86-23, revised 1985).
Transplantation
Intra-abdominal heterotopic cardiac transplantation was performed
using a modification of the method outlined by Corry and col-
leagues.11 Donor hearts were arrested with heparinized saline (100
U/1 cc), excised, and stored on ice. Through a midline abdominal
incision, the donor aorta was anastomosed to the recipient infra-
renal abdominal aorta, and the donor pulmonary artery was anas-
tomosed to the inferior vena cava with 10-0 nylon suture. Ischemia
time was 60  15 minutes. The transplanted hearts spontaneously
resumed contractions after reperfusion.
Experimental Groups
B6C.H-2bm12 strain mouse hearts were transplanted heterotopi-
cally into (1) C57Bl/6 wild-type mice or (2) IL-10 transgenic mice,
which were sacrificed at days 7 or 24 post-transplant (n  6 per
group each time point). No immunosuppression was given.
Morphometric Analysis
Elastica von Gieson stains were performed on transverse sections
of allografts and isografts. The morphometric analysis method as
previously described by Armstrong and colleagues12 was utilized.
Briefly, the areas of the neointima, media, and lumen were mea-
sured utilizing Optimas 6 software by Media Cybernetics (Silver
Springs, Md). The neointima was defined as the area bound by the
internal elastic lamina and the lumen. The media was defined as
the region between the internal and external elastic membranes.
The lumen was defined as the clear region in the vessel. At least 3
sections, 100 m apart, from the middle of the heart were utilized
for analysis. Vessels greater than 80 m in diameter were mea-
sured. More than 10 vessels per heart were examined.
Immunohistochemistry
The transplanted and native hearts were explanted in all animals.
The harvested hearts were fixed in liquid nitrogen embedded in
OCT compound, and kept at 70°C. The primary antibodies were
as follows: rat anti-mouse CD4 monoclonal antibody clone GK1.5;
rat anti-mouse CD8a monoclonal antibody clone 53-6.7; rat anti-
mouse MOMA-2 monoclonal antibody for monocytes/macro-
phages; hamster anti-mouse CD54 monoclonal antibody for inter-
cellular adhesion molecule-1 (ICAM-1) clone 3E2; rat anti-mouse
CD106 monoclonal antibody for vascular cell adhesion molecule
(VCAM)-1 clone 429; anti-mouse  smooth muscle actin mono-
clonal antibody clone 1A4 for smooth muscle cells. All primary
antibodies were purchased from PharMingen (San Diego, Calif),
with the exception of -smooth muscle actin antibody (Sigma
Chemical Co, St. Louis, Mo).
Immunohistochemistry was performed on 5-um-thick cryostat
sections with the use of an avidin-biotin-peroxidase technique
(Vector Laboratories, Inc., Burlingame, Calif) with diaminobenzi-
dine (DAB) as the chromogen. Sections were incubated with the
Avidin-Biotin Complex Solution, Vectastain Elite ABC kit, (Vec-
tor Laboratories, Inc.). DAB was applied and subsequently coun-
terstained with Harris hematoxylin.
The perivascular and vascular region was scored by two
blinded observers on a scale of 0 to 4 (0  no staining; 1 
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scattered individual cells; 2  focal clusters of cells; 3  multi-
focal cluster of cells; 4  diffuse clusters of cells).
Graft-Infiltrating Cell Isolation and Fluorescence-
Activated Cell Sorter (FACS) Analysis
Donor hearts from wild-type and IL-10 transgenic recipients, har-
vested on days 7 and 24 post-transplantation were analyzed for
graft infiltrating cells. Hearts were minced and digested for 2 hours
in Collagenase D (2 mg/mL; Worthington Biochemical, Lake-
wood, NJ) at room temperature in RPMI 1640 media (Sigma
Chemical Co.) with 10% fetal calf serum (FCS; Life Technologies,
Rockville, Md). Isolated cells were collected, washed twice in
RPMI  5% FCS, and counted after lysis of erythrocytes.
The isolated graft infiltrating cells (1-2  106/mL) were stim-
ulated with PharMingen Activation Cocktail (10 L/6 mL) (con-
taining PMA, ionomycin, and Brefeldin A) for 4 hours at 37°C.
The samples were then stained for the presence of cell surface
antigens with fluorescein isothiocyanate (FITC)-labeled anti-CD8
monoclonal antibody or FITC-labeled anti-CD4 monoclonal anti-
body for 30 minutes at 4°C. Samples were washed, then fixed and
permeablized with PharMingen Perm/Fix solution for 30 minutes
at 4°C. The cells were washed in permeablizing buffer, and incu-
bated with phycoerythrin (PE)-labeled IL-2 monoclonal antibody,
PE-labeled IFN- monoclonal antibody, PE-labeled IL-4 mono-
clonal antibody, PE-labeled IL-10 monoclonal antibody, or an
irrelevant PE-conjugated isotype-matched control antibody for 30
minutes at 4°C. After 2 washes with permeablizing buffer, the cells
were resuspended in phosphate-buffered saline. All antibodies
were purchased from PharMingen. FACS analysis of labeled cells
was carried out on a COULTER EPICS XL-MCL Flow Cytometer
(Coulter Corporation, Miami, Fla) The net percentage of cells
positive for the cell surface markers CD4 and CD8 was calculated
by subtracting the background staining (percentage of fluoro-
chrome-positive cells labeled with irrelevant isotype-matched con-
trol antibody) from the total staining (percentage of fluorochrome-
positive cells labeled with anti-CD4 or anti-CD8 antibody). The
number of fluorochrome-positive cells is reported as the number of
fluorochrome-positive cells per gram of transplanted heart.
Statistics
Data are presented as mean SEM. Analysis of variance was used
to compare mean values of cell number and intimal thickening
between different time points.
Results
Regulated IL-10 Production Attenuates CAV
Development
In this model of CAV, the donor hearts reproducibly de-
velop intimal lesions in 24 days. The expanded intima
consists of T lymphocytes, monocytes/macrophages,
smooth muscle cells, and extracellular matrix.1 All donor
hearts had palpable contractions at the time of harvest. At
Day 7, as expected, intimal thickening had not developed in
the donor hearts transplanted into either wild-type or IL-10
transgenic recipients. By day 24, B6.C-H2bm12 donor hearts
transplanted into wild-type mice developed extensive inti-
mal thickening (50  7%, Figure 1, A). In contrast with
wild-type control mice, the donor hearts transplanted into
IL-10 transgenic recipients did not develop any intimal
thickening at day 24 (0  0%; Figure 1, B).
Regulated IL-10 Production Reduces T-Lymphocyte
Recruitment
In this MHC class II mismatched model, we have previously
demonstrated that CD4 lymphocytes are absolutely re-
quired and that CD8 lymphocytes augment CAV devel-
opment.13 In this model of CAV, CD4 and CD8 lympho-
cytes infiltrate the donor heart in nearly equal numbers at
day 7 post-transplantation, whereas at 24 days, CD4 lym-
phocytes are the predominant graft infiltrating lympho-
cytes.2 Therefore, we sought to determine whether regulated
IL-10 production prevented CAV by reducing the accumu-
lation of CD4 and/or CD8 lymphocytes in the donor
heart. The number of graft infiltrating lymphocytes in the
donor hearts transplanted into IL-10 transgenic recipients
was decreased significantly at both 7 and 24 days after
Figure 1. A, B6.CH2bm12 donor hearts transplanted into C57Bl/6 wild-type recipients developed severe intimal
lesions at 24 days post-transplantation (hematoxylin and eosin [H&E] stain, magnification 100). B, In contrast,
donor hearts transplanted into IL-10 transgenic recipients had complete absence of CAV development (H&E stain,
magnification 100).
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transplantation, when compared to the donor hearts in wild-
type recipients (Figure 2). Immunohistochemical stains also
confirmed that there was a marked decline in the number of
graft infiltrating CD4 and CD8 lymphocytes in the donor
hearts of IL-10 transgenic recipients (Figures 3, B, D)
versus control recipients (Figures 3, A, C), at 24 days
post-transplantation.
Regulated IL-10 Production Attenuates Th-1 Response
of Graft Infiltrating T Lymphocytes
Intracellular cytokine assays were performed on graft-infil-
trating CD4 and CD8 lymphocytes to determine the
effect of regulated IL-10 expression on the intragraft cyto-
kine profile. Representative cytokines from both Th-1 type
(IL-2 and IFN-) and Th-2 type (IL-4, IL-10) were studied.
In wild-type mice, during the course of CAV develop-
ment, both graft-infiltrating CD4 and CD8 lymphocytes
predominately secreted the Th-1 type cytokines (ie, IL-2
and IFN-) (Figures 4, A,B). In IL-10 transgenic recipients,
there was a significant decrease in the percentage of IL-2
producing graft-infiltrating CD4 lymphocytes; however,
the percentage of IFN- producing CD4 lymphocytes re-
mained unchanged (Figure 4, A). Moreover, regulated pro-
duction of IL-10 significantly affected graft-infiltrating
CD8 lymphocytes; there was a decline in the percentage of
both IL-2 and IFN- producing graft-infiltrating CD8 lym-
phocytes (Figure 4, B). The reduction in the number of
graft-infiltrating CD4/CD8 lymphocytes and the alteration
in the cytokine profile of the residual graft infiltrating cells
resulted in marked decline in the intragraft IL-2 and IFN-
level.
Regulated IL-10 Production Reduces Monocyte/
Macrophage Recruitment
The above findings suggested that the overall expression of
Th-1 type cytokines are reduced in the donor hearts trans-
planted into IL-10 transgenic recipients. Th-1 type cyto-
kines, including IFN-, lead to the recruitment of mono-
cytes/macrophages, which are thought to participate in
CAV development. Therefore, donor hearts were tested
immunohistochemically for the presence of graft-infiltrating
monocytes/macrophages. Interestingly, correlating with the
absence of intimal thickening, there was a significant reduc-
tion in monocyte/macrophage recruitment in donor hearts
transplanted into IL-10 transgenic compared with wild-type
recipients (wild-type: 3.4  0.4 vs IL-10 transgenic: 0.7 
0.6, P  .05) (Figures 3, E,F).
Regulated IL-10 Production Does Not Alter Adhesion
Molecule Expression
IL-10 has been reported to decrease the expression of ad-
hesion molecule expression and consequently mononuclear
cell adherence.14 Therefore, donor hearts were examined
immunohistochemically for ICAM-1 and VCAM-1 expres-
sion. Notably, there were similar amounts of both ICAM-1
and VCAM-1 expression in the donor hearts transplanted
into both wild-type and IL-10 transgenic recipients (data not
shown).
Discussion
The findings of this study demonstrate that regulated pro-
duction of IL-10 inhibits the development of intimal thick-
ening, or CAV, in this model. The possible mechanisms of
this beneficial effect of IL-10 include: (1) reduction in the
number of graft-infiltrating T lymphocytes, (2) attenuation
of Th-1 type response in the graft-infiltrating T lympho-
cytes, and (3) reduction in the recruitment of intragraft
monocytes/macrophages.
Because of their anti-inflammatory nature, Th-2 type
cytokines such as IL-10 are believed to play a protective
Figure 2. Flow cytometric analysis of graft infiltrating lympho-
cytes in B6.C-H2bm12 donor hearts transplanted into either C57Bl/6
wild-type or IL-10 transgenic recipients. A, At 7 days post-trans-
plantation, there was a significant decrease in CD4 and CD8
lymphocyte recruitment to the donor hearts transplanted into
IL-10 transgenic compared to wild-type recipients (P < .05). B, At
day 24, there is a persistent decrease in intragraft T lymphocyte
subset recruitment in IL-10 transgenic recipients (P < .05 when
compared to donor hearts harvested from control recipients).
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role in the prevention of chronic rejection.5-7 A number of
immunologic tools have been used to test the effect of IL-10
overexpression on allograft rejection, including (1) treat-
ment of transplant recipients with either cytokine blocking
antibodies or recombinant proteins, (2) transfection of do-
nor hearts with cytokine gene constructs, and (3) transplan-
tation of donor hearts into cytokine knockout recipients.5-
7,15-17 Notably, these studies have relied upon unphysiologic
expression of IL-10. The IL-10 transgenic mouse employed
in the current study provides a unique immunologic tool for
assessing the role of IL-10 in the prevention of chronic
rejection. IL-10 synthesis is transient, local, and related to T
lymphocyte activation, thereby avoiding the toxic effects of
either constitutive expression, or very high levels of IL-
10.10 It is important to mention that prior studies have
demonstrated that the IL-10 transgenic mice do not exhibit
any defects in growth/development and have normal num-
bers/phenotypes of T and B lymphocytes. Furthermore, the
amount of IL-10 synthesized in these mice is not sufficient
to cause a complete suppression of Th-1 cytokines.10
Regulated expression of IL-10 reduces T lymphocyte
subset graft infiltration. The central finding of this study is
that localized, transient, and regulated expression of IL-10
prevents CAV development in this murine model. Analysis
of the graft-infiltrating mononuclear cells illustrated that
there was a significant reduction in the number of CD4 and
CD8 lymphocytes at all time points. Development of CAV
in this murine strain combination is strictly dependent on
cellular alloimmunity.1 Our prior studies have shown that
CD4 lymphocytes were absolutely required for the devel-
opment of chronic rejection, whereas CD8 lymphocytes
augmented CAV.1 The reduction in graft-infiltrating lym-
phocytes in the donor hearts in the IL-10 transgenic recip-
ients may be due to (1) decreased recruitment or (2) alter-
ation in priming of the recipient T cells.
IL-10 has been shown to block upregulation of adhesion
molecules, thereby reducing T lymphocyte emigration.14 In
this model, we could not detect a significant downregulation
in the adhesion molecules ICAM-1 and VCAM-1, which are
known to mediate mononuclear cell recruitment. Alterna-
tively, decreased T-lymphocyte recruitment in IL-10 trans-
genic recipients may be due to the attenuation of chemo-
tactic mediators. We have recently observed an important
role for the CXC chemokines, and specifically for monokine
induced by IFN- (Mig/CXCL9), in T-lymphocyte recruit-
ment in this strain combination.19 Neutralization of Mig/
CXCL9 significantly reduced T-lymphocyte recruitment
and CAV development.19a The effects of IL-10 on Mig/
CXCL9 production was recently studied by Aliberti and
colleagues,20 who showed that IL-10 inhibited Mig/CXCL9
production. Additionally, given that Mig/CXCL9 produc-
tion is strictly dependent on IFN-, IL-10 may have addi-
tional regulatory effects on Mig/CXCL9 production via its
inhibitory effects on IFN-.
Aside from a decrease in recruitment, the number of graft
infiltrating T lymphocytes may be reduced due to the inhib-
itory effects of IL-10 on T lymphocyte priming/prolifera-
tion. IL-10 reduces antigen-specific T-lymphocyte prolifer-
ation by diminishing the antigen presenting capabilities of
APCs; IL-10 downregulates the expression of MHC class II,
co-stimulatory molecules, and cytokine production by
APCs.20 Li and colleagues18 have shown that IL-10 inhib-
ited T-lymphocyte proliferation by impairing the function of
APCs, prior to antigen exposure. Furukawa and colleagues7
also illustrated that IL-10 caused a dose-dependent decrease
in alloantigen specific T-lymphocyte proliferation in mixed
Figure 2. Cont’d. C, Representative flow cytometry dot plots gated on graft infiltrating cells at day 24 post-
transplantation. There was a marked reduction in the number of infiltrated CD4 lymphocytes into the donor hearts
of IL-10 transgenic recipients (right) when compared to wild-type control recipients (left).
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lymphocyte reactions. Hence, the decrease in the number of
graft-infiltrating T lymphocytes in the donor hearts in the
IL-10 transgenic recipients may be due to a reduction in
T-lymphocyte recruitment as well as inhibition of T-lym-
phocyte proliferation.
Regulated expression of IL-10 suppresses IFN- pro-
duction. IL-10 inhibits Th1 cytokine production (ie,
IFN-) by CD4 lymphocytes both in vivo and in vitro.21
IL-10 overexpression in this model resulted in marked re-
duction in the number of graft infiltrating lymphocytes as
Figure 3. Representative immunohistochemical sections of donor hearts harvested at 24 days post-transplantation
from wild-type control recipients and IL-10 transgenic recipients. Donor hearts transplanted into C57Bl/6 wild-type
recipients developed severe intimal lesions, associated with (A) CD4 lymphocyte, (C) CD8 lymphocyte, and (E)
monocyte/macrophage recruitment. In contrast, there was a marked decline in the number of graft infiltrating (B)
CD4 lymphocytes, (D) CD8 lymphocytes, and (F) monocyte/macrophages in the donor hearts transplanted in the
IL-10 transgenic recipients. Representative sections are from donor hearts harvested at 24 days post-transplan-
tation. All panels in this figure are immunohistochemical stains using the avidin-biotin-peroxidase technique.
Positive cells display a brown stain.
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well as suppression of Th1-like cytokine production by the
residual infiltrated T lymphocytes. The net effect was a
significant reduction in the total intragraft IFN- level in the
donor hearts transplanted into IL-10 transgenic recipients
when compared to wild-type recipients. IFN- is known to
play a central role in the development of CAV in this strain
combination.8,9 Nagano and colleagues8,9 previously re-
ported that the serological neutralization or genetic absence
of IFN-, markedly reduced the extent of chronic rejection.
IFN- may contribute to CAV development through a num-
ber of mechanisms. Tellides and colleagues22 have reported
that IFN- alone could induce arteriosclerotic changes in
either swine or human arterial loops that were transplanted
into immunodeficient mouse recipients.22 Alternatively,
IFN- is know to play a role in the activation of macro-
phages, which have been suggested as key effector cells in
CAV development.23-26 Thus, suppression of IFN- pro-
duction by local expression of IL-10 can affect CAV devel-
opment in this model via 2 pathways: (1) directly, and (2) by
controlling macrophage activation.
Regulated IL-10 Expression Reduces Monocyte Re-
cruitment. Immunohistochemically, we observed a signif-
icant decrease in both macrophage recruitment and lesion
development in the presence of IL-10 expression. The bio-
logical effect(s) of IL-10 on macrophage recruitment and
activation have been studied by several investigators. Mo-
stafa Mtairag and colleagues27 illustrated that IL-10 de-
creased monocyte/endothelial cell adhesion via the modu-
lation of monocyte/macrophage adhesion molecules, CD18
and CD62L. O’Farrell and colleagues28 reported that IL-10
inhibited macrophage proliferation in vitro in a dose-depen-
dent fashion; inhibition was due to G1 cell cycle growth
arrest, and not apoptosis. Finally, because IFN- is known
to play a role in the activation of macrophages, IL-10 can
control macrophage activation, indirectly, via a reduction in
intragraft IFN- levels.23-26 The net effect of local and
transient IL-10 production is a reduction in monocyte/mac-
rophage recruitment.
A limitation of this study is that CAV development in
IL-10 transgenic recipients was assessed up to 24 days after
transplantation. It is conceivable that regulated IL-10 ex-
pression may delay CAV development; examination of later
time points will be necessary to document eradication of
CAV development in the donor hearts of IL-10 transgenic
recipients.
This study expands the current body of knowledge on the
role of IL-10 in the alloimmune response; it emphasizes the
importance of the location, duration, and timing of IL-10
expression on its biologic effect in vivo. It also supports
IL-10 gene-based therapy directed at the recipients. A po-
tential strategy may include transfer of IL-10 gene under
IL-2 promoter to the recipient’s hematopoietic stem cells
while on the waiting list. The transduced recipient cells will
produce IL-10 only when activated (ie, IL-2 promoter is
activated). However, it is important to note that the effect of
immunosuppressive medications on the overexpression of
IL-10 and its beneficial effects are unknown.
In conclusion, this study provides important insight on
the role of IL-10 in alloimmune responses. It suggests that
regulated IL-10 expression can attenuate chronic rejection
in a murine model. The abrogation of CAV appears to
correlate with the reduction of graft-infiltrating T lympho-
cytes and macrophages, and consequently, intragraft IFN-
production. The results of this study justify and support
ongoing IL-10 gene-based therapies in solid organ trans-
plantation.
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